I agree that this site is using cookies. You can find further informations here.
X
Moguem Soubgui, Arlette Flore
36  results:
Search for persons X
?
1

Serological surveillance reveals a high exposure to SARS-Co..:

Moguem Soubgui, Arlette Flore ; Ndeme Mboussi, Wilfred Steve ; Kojom Foko, Loick Pradel...
PLOS Global Public Health.  4 (2024)  2 - p. e0002380 , 2024
Link: https://doi.org/10.1371/..
 
?
2

Exploring demographical, clinical, and dietary determinants..:

Moguem Soubgui, Arlette Flore ; Ndeme Mboussi, Wilfried Steve ; Kojom Foko, Loick Pradel..
Heliyon.  10 (2024)  3 - p. e24926 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Confounding role of comorbidities and COVID-19 vaccination ..:

Moguem Soubgui, Arlette Flore ; Kojom Foko, Loick Pradel ; Embolo Enyegue, Elisée Libert...
IJID Regions.  8 (2023)  - p. 129-136 , 2023
Link: https://doi.org/10.1016/..
 
?
4

Epidemiological situation of SARS-CoV-2 infection in Douala..:

Moguem Soubgui, Arlette Flore ; Embolo Enyegue, Elisee Libert ; Kojom Foko, Loick Pradel...
Acta Tropica.  241 (2023)  - p. 106864 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Crude SARS-CoV-2 seroprevalence profile by months and healt..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s003.  , 2024
Link: https://doi.org/10.1371/..
 
?
6

Crude SARS-CoV-2 seroprevalence profile by clinical symptom:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s004.  , 2024
Link: https://doi.org/10.1371/..
 
?
7

Flow diagram of the study:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g001.  , 2024
Link: https://doi.org/10.1371/..
 
?
8

Testing SARS-CoV-2 immune response parameters (IgM, IgG, CD..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s002.  , 2024
Link: https://doi.org/10.1371/..
 
?
9

Overall variation of CD4+ (A, D), IFN-γ (B, E) and IL-6 (C,..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g005.  , 2024
Link: https://doi.org/10.1371/..
 
?
10

Clinical value of symptoms for prognostic of IgM seropositi..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s005.  , 2024
Link: https://doi.org/10.1371/..
 
?
11

Fig 2 -:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g002.  , 2024
Link: https://doi.org/10.1371/..
 
?
12

Univariate logistic regression between SARS-CoV-2 antibodie..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t002.  , 2024
Link: https://doi.org/10.1371/..
 
?
13

Predictors of the presence of anti-SARS-CoV-2 antibodies am..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t004.  , 2024
Link: https://doi.org/10.1371/..
 
?
14

Crude prevalence of SARS–CoV–2 antibodies by study sites:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g003.  , 2024
Link: https://doi.org/10.1371/..
 
?
15

Univariate logistic regression between SARS-CoV-2 antibodie..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t002.  , 2024
Link: https://doi.org/10.1371/..
 
1-15